105 related articles for article (PubMed ID: 32682188)
1. Histopathological subtyping is a prognostic factor in stage IV lung adenocarcinoma.
Da Cruz V; Yvorel V; Casteillo F; Tissot C; Luchez A; Bayle-Bleuez S; Fournel P; Tiffet O; Péoc'h M; Forest F
Lung Cancer; 2020 Sep; 147():77-82. PubMed ID: 32682188
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma.
Qian F; Yang W; Wang R; Xu J; Wang S; Zhang Y; Jin B; Yu K; Han B
J Thorac Cardiovasc Surg; 2018 Mar; 155(3):1227-1235.e2. PubMed ID: 29223834
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas.
Schilsky JB; Ni A; Ahn L; Datta S; Travis WD; Kris MG; Chaft JE; Rekhtman N; Hellmann MD
Lung Cancer; 2017 Jun; 108():205-211. PubMed ID: 28625636
[TBL] [Abstract][Full Text] [Related]
4. Nonpredominant lepidic pattern correlates with better outcome in invasive lung adenocarcinoma.
Mäkinen JM; Laitakari K; Johnson S; Mäkitaro R; Bloigu R; Lappi-Blanco E; Kaarteenaho R
Lung Cancer; 2015 Dec; 90(3):568-74. PubMed ID: 26506915
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive evaluation of clinicopathologic characteristics, molecular features and prognosis in lung adenocarcinoma with solid component.
Li J; You W; Zheng D; Yan B; Ma X; Pan Y; Zhang Y; Li Y; Shen X; Cheng X; Sun Y; Chen H
J Cancer Res Clin Oncol; 2018 Apr; 144(4):725-734. PubMed ID: 29368062
[TBL] [Abstract][Full Text] [Related]
6. Impact of Solid Minor Histologic Subtype in Postsurgical Prognosis of Stage I Lung Adenocarcinoma.
Chen T; Luo J; Gu H; Gu Y; Huang Q; Wang Y; Zheng J; Yang Y; Chen H
Ann Thorac Surg; 2018 Jan; 105(1):302-308. PubMed ID: 29162222
[TBL] [Abstract][Full Text] [Related]
7. Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations.
Park JY; Jang SH; Kim HI; Kim JH; Park S; Hwang YI; Jung KS; Seo J; Lee CY; Ko Y; Park YB
BMC Cancer; 2019 Jun; 19(1):574. PubMed ID: 31196060
[TBL] [Abstract][Full Text] [Related]
8. Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy.
Chang S; Hur J; Hong YJ; Lee HJ; Kim YJ; Han K; Choi BW
AJR Am J Roentgenol; 2018 Jan; 210(1):43-51. PubMed ID: 29091002
[TBL] [Abstract][Full Text] [Related]
9. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
[TBL] [Abstract][Full Text] [Related]
10. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.
Russell PA; Barnett SA; Walkiewicz M; Wainer Z; Conron M; Wright GM; Gooi J; Knight S; Wynne R; Liew D; John T
J Thorac Oncol; 2013 Apr; 8(4):461-8. PubMed ID: 23486266
[TBL] [Abstract][Full Text] [Related]
11. Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy.
Leeman JE; Rimner A; Montecalvo J; Hsu M; Zhang Z; von Reibnitz D; Panchoo K; Yorke E; Adusumilli PS; Travis W; Wu AJ
Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):138-145. PubMed ID: 27839909
[TBL] [Abstract][Full Text] [Related]
12. Pathologic Subtypes of Lung Adenocarcinoma Brain Metastasis Is a Strong Predictor of Survival After Resection.
Casteillo F; Guy JB; Dal-Col P; Karpathiou G; Pommier B; Bayle-Bleuez S; Fournel P; Vassal F; Forest F
Am J Surg Pathol; 2018 Dec; 42(12):1701-1707. PubMed ID: 30222604
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB.
Luo J; Huang Q; Wang R; Han B; Zhang J; Zhao H; Fang W; Luo Q; Yang J; Yang Y; Zhu L; Chen T; Cheng X; Wang Y; Zheng J; Wu H; Xia W; Chen H
J Cancer Res Clin Oncol; 2016 Sep; 142(9):2031-40. PubMed ID: 27379889
[TBL] [Abstract][Full Text] [Related]
14. Solid predominant histologic subtype and early recurrence predict poor postrecurrence survival in patients with stage I lung adenocarcinoma.
Luo J; Wang R; Han B; Zhang J; Zhao H; Fang W; Luo Q; Yang J; Yang Y; Zhu L; Chen T; Cheng X; Huang Q; Wang Y; Zheng J; Chen H
Oncotarget; 2017 Jan; 8(4):7050-7058. PubMed ID: 27732964
[TBL] [Abstract][Full Text] [Related]
15. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
16. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
[TBL] [Abstract][Full Text] [Related]
17. The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma.
Oktay E; Oflazoglu U; Varol Y; Tanriverdi O; Mermur N; Arda HU; Demir L; Keskin O; Ahmadli T; Somali I; Oztop I; Meydan N
J Cancer Res Ther; 2020; 16(4):737-744. PubMed ID: 32930112
[TBL] [Abstract][Full Text] [Related]
18. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.
Warth A; Muley T; Meister M; Stenzinger A; Thomas M; Schirmacher P; Schnabel PA; Budczies J; Hoffmann H; Weichert W
J Clin Oncol; 2012 May; 30(13):1438-46. PubMed ID: 22393100
[TBL] [Abstract][Full Text] [Related]
19. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of the effect of different pathological subtypes to prognosis in stage I pulmonary adenocarcinoma].
Jiang W; Xi J; Xu S; Lu S; Wang Q
Zhonghua Wai Ke Za Zhi; 2015 Oct; 53(10):737-41. PubMed ID: 26654304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
